Companion Diagnostics Market
Report Code
MD 5463
Published in
Jun, 2026, By MarketsandMarkets™
Companion Diagnostics Market by Product (Assays, Kits, & Reagents, Instruments, Software), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious), Drug Class (MAB, Cell & Gene Therapy) - Global Forecast to 2031
USD 11.57 BN
MARKET SIZE, 2031
CAGR 12.9%
(2026-2031)
500
REPORT PAGES
560
MARKET TABLES
COMPANION DIAGNOSTICS MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global companion diagnostics market is projected to grow from USD 6.31 billion in 2026 to USD 11.57 billion by 2031, at a CAGR of 12.9% during the forecast period. The market was valued at USD 5.66 billion in 2025. The market is driven by the rapid adoption of precision medicine, targeted therapies, and biomarker-based treatment approaches. Companion diagnostics (CDx) are essential for identifying patient populations most likely to benefit from specific therapies, particularly in oncology, autoimmune diseases, and rare genetic disorders. The market encompasses diagnostic assays, next-generation sequencing (NGS), PCR-based testing, immunohistochemistry, in situ hybridization, liquid biopsy technologies, bioinformatics platforms, and associated analytical services. Increasing regulatory emphasis on personalized therapeutics, growing pharma-diagnostic partnerships, and expanding approvals of targeted drugs are accelerating market growth globally.
KEY TAKEAWAYS
-
BY REGIONNorth America accounted for the largest share of 44.7% in 2025.
-
BY PRODUCT & SERVICEThe assays, kits & reagents segment captured 67.3% of the total market in 2025.
-
BY END USERPharmaceutical & biotechnology companies dominated the companion diagnostics market in 2025.
-
COMPETITIVE LANDSCAPE - Key PlayersF. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), and Thermo Fisher Scientific Inc. (US) were identified as stars in the companion diagnostics market, given their strong market share and product and service footprint.
-
COMPETITIVE LANDSCAPE - StartupsPillar Biosciences (US) and Biocartis (Belgium) have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The companion diagnostics market is expanding rapidly, driven by the increasing adoption of precision medicine, rising approvals of targeted therapies, and growing integration of biomarker-based testing into clinical decision-making. Advances in molecular diagnostics, NGS, liquid biopsy, and AI-enabled biomarker discovery are accelerating the adoption of companion diagnostics across drug development, oncology research, and personalized treatment applications.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The companion diagnostics market is rapidly transforming, driven by advances in precision medicine, NGS, liquid biopsy, and AI-enabled biomarker discovery platforms. The growing integration of companion diagnostics into targeted drug development and clinical trial stratification is accelerating demand for highly accurate, personalized diagnostic solutions across oncology and rare disease applications. The rising adoption of liquid biopsy and minimally invasive testing is disrupting traditional tissue-based diagnostic workflows by enabling real-time disease monitoring, therapy response assessment, and early mutation detection. In parallel, advances in digital pathology, multiplex biomarker analysis, cloud-based bioinformatics, and AI-driven clinical interpretation are improving diagnostic precision, turnaround time, and treatment decision support. Strategic collaborations between pharmaceutical companies and molecular diagnostics developers, along with evolving regulatory frameworks that support co-development of drugs and companion diagnostics, are strengthening commercialization opportunities. The expanding use of companion diagnostics beyond oncology into cardiovascular, autoimmune, and infectious diseases is further broadening market potential across hospitals, reference laboratories, CROs/CDMOs, and precision medicine research centers.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Increasing adoption of precision medicine and targeted therapies
-
Growing investments in genomics, molecular diagnostics, and biomarker discovery
RESTRAINTS
Impact
Level
Level
-
High development, clinical validation, and regulatory approval costs
OPPORTUNITIES
Impact
Level
Level
-
Expansion of liquid biopsy and non-invasive companion diagnostics
-
AI-driven biomarker interpretation and digital pathology integration
CHALLENGES
Impact
Level
Level
-
Regulatory complexity associated with simultaneous drug–diagnostic approvals
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Increasing adoption of precision medicine and targeted therapies
The growing focus on precision medicine is significantly driving demand for companion diagnostics, as healthcare providers increasingly rely on biomarker-based testing to personalize treatment decisions. The rising approvals of targeted therapies, particularly in oncology, are accelerating the integration of companion diagnostics into clinical workflows. Pharmaceutical companies are increasingly partnering with diagnostic developers to improve patient stratification and treatment efficacy.
Restraint: High development, clinical validation, and regulatory approval costs
Developing companion diagnostics requires substantial investment in biomarker discovery, assay development, clinical validation, and regulatory compliance. Simultaneous approval requirements for therapeutics and diagnostics increase development complexity and extend commercialization timelines. Smaller diagnostic companies often face financial and operational challenges in conducting large-scale validation studies. Reimbursement policy variability and limited coverage for molecular testing in certain regions further restrict market penetration. In addition, evolving global regulatory standards create additional compliance burdens for market participants.
Opportunity: Expansion of liquid biopsy and non-invasive companion diagnostics
The growing adoption of liquid biopsy technologies presents significant growth opportunities for the companion diagnostics market by enabling minimally invasive cancer detection and treatment monitoring. Liquid biopsy-based companion diagnostics improve patient convenience and support real-time assessment of tumor mutations and treatment response. Advancements in circulating tumor DNA (ctDNA), multi-cancer early detection, and AI-driven biomarker analysis are expanding the scope of precision diagnostics. Growing demand for decentralized and rapid testing solutions is further driving innovation in non-invasive diagnostic platforms. Expanding applications beyond oncology into rare and infectious diseases also offer long-term market potential.
Challenge: Regulatory complexity associated with simultaneous drug–diagnostic approvals
Companion diagnostics face significant regulatory challenges because both the therapeutic product and the associated diagnostic test must be approved in coordination. Differences in regulatory frameworks across regions complicate global commercialization strategies. Delays in aligning clinical trials, validating biomarkers, and submitting regulatory applications can affect product launch timelines and increase overall development costs. Ensuring analytical accuracy, reproducibility, and clinical utility across diverse patient populations remains a major challenge for diagnostic developers. Furthermore, evolving regulatory expectations regarding AI-enabled diagnostics and real-world evidence are adding additional layers of compliance complexity.
COMPANION DIAGNOSTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Develops companion diagnostics linked with targeted oncology therapies using PCR, IHC, and NGS platforms to identify biomarker-positive patient populations for therapies such as HER2, EGFR, and PD-L1 targeted treatments. | Enables accurate patient stratification, improves therapy response rates, and supports faster clinical decision-making in precision oncology. |
 |
Provides companion diagnostic assays through Dako pathology platforms, including PD-L1 and immunohistochemistry-based biomarker testing for immuno-oncology applications. | Improves biomarker detection consistency, supports immunotherapy adoption, and enhances pathology workflow standardization. |
 |
Provides therascreen companion diagnostic assays for detecting specific gene mutations across cancer indications, supporting therapy selection for targeted drugs in lung, colorectal, and breast cancers. | Enhances treatment selection accuracy, reduces ineffective therapies, and supports regulatory-approved personalized treatment pathways. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The companion diagnostics market is a highly interconnected precision medicine ecosystem in which pharmaceutical and biopharmaceutical companies, diagnostic assay developers, sequencing and pathology platform providers, reference laboratories, hospitals, oncology centers, academic institutions, and regulatory bodies collaborate to enable biomarker-driven treatment decisions. Pharmaceutical companies work closely with in vitro diagnostic manufacturers and specialized molecular diagnostics firms to co-develop and commercialize companion diagnostic tests alongside targeted therapies, immunotherapies, and emerging cell and gene therapies. Diagnostic ecosystem participants provide assays, kits, reagents, instruments, sequencing platforms, IHC/ISH systems, bioinformatics tools, and interpretation software to identify actionable biomarkers such as EGFR, ALK, HER2, KRAS, BRAF, BRCA, PD-L1, MSI/MMR, NTRK, RET, and MET. Reference laboratories, hospital molecular pathology labs, and cancer centers support clinical implementation by performing CDx testing, reporting actionable results, and integrating biomarker data into oncology treatment pathways. CROs and specialized clinical research service providers support biomarker discovery, assay validation, clinical trial patient selection, regulatory submissions, and post-commercialization testing strategies. Regulatory authorities such as the US FDA, EMA, PMDA, and other national agencies, along with payers and health technology assessment bodies, shape the ecosystem through approval pathways, clinical utility requirements, reimbursement policies, and companion diagnostic labeling standards.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Global Companion Diagnostics Market, by Product & Service
Assays, kits & reagents are expected to account for the largest share of the companion diagnostics market due to their recurring use across PCR, NGS, IHC, and ISH-based testing workflows. These consumables are required for every patient test, unlike instruments, which are capital purchases with longer replacement cycles. Growing biomarker testing volumes in oncology, especially for lung, breast, and colorectal cancers and hematologic malignancies, continue to support demand for CDx assay kits and reagents.
Global Companion Diagnostics Market, by Technology
PCR is expected to hold the largest share of the companion diagnostics market due to its wide clinical use, faster turnaround time, lower cost, and strong adoption across targeted mutation testing workflows. PCR-based CDx assays are widely used for actionable biomarkers such as EGFR, KRAS/NRAS, BRAF, BRCA mutations, MSI-related testing, and selected infectious or oncology-linked molecular targets.
Global Companion Diagnostics Market, by Indication
Cancer is expected to dominate the companion diagnostics market, accounting for the vast majority of demand. Within cancer, lung cancer is likely to hold the largest share, driven by a high number of actionable biomarkers, including EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS, and PD-L1, as well as broader NGS-based profiling. Breast cancer and colorectal cancer also represent major CDx indications, supported by HER2, ER/PR, BRCA/HRD, RAS, BRAF, and MSI/MMR testing.
Global Companion Diagnostics Market, by Sample
Tissue samples are expected to hold the largest share of the companion diagnostics market because most approved and reimbursed CDx workflows remain tissue-based. Tissue testing is central to IHC, ISH/FISH, and many NGS assays used in solid tumors, especially for HER2, PD-L1, ALK, MMR, and comprehensive tumor profiling.
Global Companion Diagnostics Market, by End User
Pharmaceutical & biopharmaceutical companies are expected to account for the largest share of the companion diagnostics market because of their central role in CDx co-development, clinical trial patient selection, regulatory submissions, and the commercialization of targeted therapies. These companies drive demand for companion diagnostic assays throughout drug development and post-approval use, particularly across oncology, immunotherapy, and precision medicine pipelines.
REGION
Asia Pacific to be fastest-growing region during forecast period
During the forecast period, Asia Pacific is expected to be the fastest-growing region in the companion diagnostics market, driven by rising cancer incidence, expanding adoption of precision oncology, increasing use of PCR- and NGS-based biomarker testing, and improving access to targeted therapies across China, Japan, South Korea, Australia, and India. Japan and South Korea are advancing reimbursement and clinical adoption of comprehensive genomic profiling, while China and India are witnessing rapid expansion of molecular diagnostics infrastructure, oncology reference laboratories, and pharma-led biomarker testing programs. Growing clinical trial activity, increasing approvals of targeted therapies, and broader use of liquid biopsy and multi-gene testing are expected to further support regional growth. However, adoption will remain uneven across the region due to differences in reimbursement maturity, testing affordability, and access to advanced oncology care.
COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
F. Hoffmann-La Roche AG is a leading player in the companion diagnostics market, supported by its broad portfolio spanning tissue diagnostics, immunohistochemistry, in situ hybridization, PCR-based testing, and comprehensive genomic profiling through Foundation Medicine. The company has strong pharmaceutical linkages, regulatory experience, and a wide installed base across pathology and oncology testing workflows, positioning it well in therapy-linked biomarker testing. Guardant Health and Tempus are emerging high-growth players, supported by liquid biopsy, AI-enabled molecular profiling, and the extensive use of NGS-based companion diagnostics in advanced oncology.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- F. Hoffmann-La Roche AG (Switzerland)
- Agilent Technologies, Inc. (US)
- QIAGEN (Netherlands)
- Thermo Fisher Scientific Inc. (US)
- Danaher (US)
- Guardant Health, Inc (US)
- Abbott (US)
- Illumina, Inc. (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 5.66 BN |
| Market Forecast in 2031 (Value) | USD 11.57 BN |
| Growth Rate | CAGR of 12.9 from 2026 to 2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD BN/MN) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
WHAT IS IN IT FOR YOU: COMPANION DIAGNOSTICS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Evaluate competitive positioning of key players in the companion diagnostics market | Benchmarked leading companies across CDx assays, kits, reagents, instruments/systems, NGS platforms, IHC/ISH solutions, liquid biopsy tests, bioinformatics, and reference laboratory services based on technology coverage, approved CDx portfolio, pharma partnerships, geographic reach, regulatory approvals, and end-user focus. | Identifies competitive gaps, partnership opportunities, and differentiation strategies |
| Assess high-growth technologies and segment opportunities in companion diagnostics | Evaluated growth potential across PCR, NGS, IHC, ISH/FISH, liquid biopsy, tissue-based testing, blood-based testing, and software-enabled interpretation workflows, including differences in adoption across oncology, infectious disease, cardiovascular, neurological, and other indications | Supports investment prioritization, product development, CDx co-development planning, regional expansion, and technology roadmap decisions, especially around NGS, liquid biopsy, and biomarker-driven oncology testing |
RECENT DEVELOPMENTS
- May 2026 : F. Hoffmann-La Roche AG agreed to acquire PathAI to strengthen its digital pathology and AI-enabled precision diagnostics capabilities. The deal builds on Roche and PathAI’s earlier collaboration, which expanded in 2024 to include AI-enabled companion diagnostic algorithm development, supporting Roche’s position in tissue-based oncology diagnostics and biomarker interpretation
- December 2025 : The FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu in combination with F. Hoffmann-La Roche AG's Perjeta for first-line treatment of HER2-positive metastatic breast cancer, with the approval linked to FDA-approved companion diagnostic testing for HER2-positive patient identification. This reinforces the continued importance of HER2 testing in therapy selection.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
40
2
EXECUTIVE SUMMARY
45
3
PREMIUM INSIGHTS
50
4
MARKET OVERVIEW
Precision medicine and genomics investments drive growth amid regulatory and cost challenges in diagnostics.
54
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.1.1
INCREASING ADOPTION OF PRECISION MEDICINE AND TARGETED THERAPIES
4.2.1.2
GROWING INVESTMENTS IN GENOMICS, MOLECULAR DIAGNOSTICS, AND BIOMARKER DISCOVERY
4.2.1.3
EXPANDING PHARMACEUTICAL-DIAGNOSTIC CO-DEVELOPMENT PARTNERSHIPS
4.2.2
RESTRAINTS
4.2.2.1
HIGH DEVELOPMENT, CLINICAL VALIDATION, AND REGULATORY APPROVAL COSTS
4.2.3
OPPORTUNITIES
4.2.3.1
EXPANSION OF LIQUID BIOPSY AND NON-INVASIVE COMPANION DIAGNOSTICS
4.2.3.2
AI-DRIVEN BIOMARKER INTERPRETATION AND DIGITAL PATHOLOGY INTEGRATION
4.2.4
CHALLENGES
4.2.4.1
REGULATORY COMPLEXITY ASSOCIATED WITH SIMULTANEOUS DRUG-DIAGNOSTIC APPROVALS
4.3
UNMET NEEDS & WHITE SPACES
4.3.1
UNMET NEEDS IN COMPANION DIAGNOSTICS MARKET
4.3.2
WHITE SPACE OPPORTUNITIES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1
INTERCONNECTED MARKETS
4.4.2
CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1
KEY MOVES & STRATEGIC FOCUS
5
INDUSTRY TRENDS
Navigate competitive dynamics and pricing shifts to leverage opportunities in companion diagnostics.
68
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
BARGAINING POWER OF SUPPLIERS
5.1.2
BARGAINING POWER OF BUYERS
5.1.3
THREAT OF NEW ENTRANTS
5.1.4
THREAT OF SUBSTITUTES
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
5.2
MACROECONOMIC OUTLOOK
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS & FORECAST
5.2.3
TRENDS IN GLOBAL COMPANION DIAGNOSTICS INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.4
VALUE CHAIN ANALYSIS
5.5
ECOSYSTEM ANALYSIS
5.6
PRICING ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024–2026
5.6.2
AVERAGE SELLING PRICE TREND, BY REGION, 2024–2026
5.6.3
AVERAGE SELLING PRICE TREND, BY TECHNOLOGY TYPE, 2024–2026
5.7
TRADE ANALYSIS
5.7.1
IMPORT SCENARIO (HS CODE 3822)
5.7.2
EXPORT SCENARIO (HS CODE 3822)
5.8
KEY CONFERENCES & EVENTS, 2026–2027
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.10
INVESTMENT & FUNDING SCENARIO
5.11
IMPACT OF US TARIFFS—COMPANION DIAGNOSTICS MARKET
5.11.1
INTRODUCTION
5.11.2
KEY TARIFF RATES
5.11.3
PRICE IMPACT ANALYSIS
5.11.4
IMPACT ON COUNTRIES/REGIONS
5.11.4.1
NORTH AMERICA
5.11.4.2
EUROPE
5.11.4.3
ASIA PACIFIC
5.11.5
IMPACT ON END-USE INDUSTRIES
5.11.5.1
HOSPITAL AND CANCER CENTERS
5.11.5.2
PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
5.11.5.3
OTHER END USERS
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations revolutionize genomic profiling, enhancing precision diagnostics and shaping future healthcare landscapes.
91
6.1
KEY EMERGING TECHNOLOGIES
6.1.1
NEXT-GENERATION SEQUENCING (NGS)-BASED COMPREHENSIVE GENOMIC PROFILING
6.1.2
LIQUID BIOPSY (CFDNA/CTDNA TESTING)
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
BIOINFORMATICS & AI-DRIVEN CLINICAL INTERPRETATION
6.2.2
MULTIPLEX PCR/QPCR PLATFORMS
6.3
ADJACENT TECHNOLOGIES
6.3.1
DIGITAL PATHOLOGY & AI-BASED IMAGING
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.5
PATENT ANALYSIS
6.5.1
LIST OF MAJOR PATENTS
6.6
FUTURE APPLICATIONS
6.7
IMPACT OF AI/GENERATIVE AI ON COMPANION DIAGNOSTICS MARKET
6.7.1
INTRODUCTION
6.7.2
TOP USE CASES & MARKET POTENTIAL
6.7.3
KEY COMPANIES IMPLEMENTING AI
6.7.4
FUTURE OF AI
7
REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
Navigate complex global regulations with insights into sustainability and eco-friendly initiatives.
100
7.1
REGIONAL REGULATIONS & COMPLIANCE
7.1.1
REGULATORY ANALYSIS
7.1.1.1
NORTH AMERICA
7.1.1.1.1
US
7.1.1.1.2
CANADA
7.1.1.2
EUROPE
7.1.1.2.1
GERMANY
7.1.1.2.2
UK
7.1.1.2.3
FRANCE
7.1.1.2.4
ITALY
7.1.1.3
ASIA PACIFIC
7.1.1.3.1
CHINA
7.1.1.3.2
JAPAN
7.1.1.3.3
INDIA
7.1.1.3.4
AUSTRALIA
7.1.1.4
LATIN AMERICA
7.1.1.4.1
BRAZIL
7.1.1.4.2
MEXICO
7.1.1.5
MIDDLE EAST
7.1.1.5.1
AFRICA
7.1.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
SUSTAINABILITY INITIATIVES
7.2.1
ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES
7.2.1.1
ECO-FRIENDLY INITIATIVES
7.2.2
SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlock hidden revenue by addressing unmet needs and overcoming adoption barriers in buyer dynamics.
110
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2
BUYING CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
8.5
MARKET PROFITABILITY
8.5.1
REVENUE POTENTIAL
8.5.2
COST DYNAMICS
9
COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables
116
9.1
INTRODUCTION
9.2
ASSAYS, KITS, AND REAGENTS
9.2.1
INCREASING ROUTINE USE OF BIOMARKER-BASED TESTING FOR TARGETED THERAPY AND IMMUNOTHERAPY SELECTION
9.3
INSTRUMENTS/SYSTEMS
9.3.1
RISING ADOPTION OF AUTOMATED MOLECULAR, PATHOLOGY, AND NGS PLATFORMS TO SUPPORT STANDARDIZED AND SCALABLE CDX TESTING
9.4
SOFTWARE & SERVICES
9.4.1
INCREASING DEMAND FOR HIGH-VALUE NGS INTERPRETATION, LIQUID BIOPSY SERVICES, PHARMA CDX CO-DEVELOPMENT, AND CLINICALLY ACTIONABLE REPORTING
10
COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables
131
10.1
INTRODUCTION
10.2
TISSUE SAMPLES
10.2.1
CONTINUED DOMINANCE OF TISSUE-BASED BIOMARKER TESTING IN ONCOLOGY TREATMENT SELECTION
10.3
BLOOD SAMPLES
10.3.1
RAPID ADOPTION OF LIQUID BIOPSY AND CIRCULATING TUMOR DNA-BASED COMPANION DIAGNOSTICS TO DRIVE MARKET
10.4
OTHER SAMPLE TYPES
11
COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 36 Data Tables
144
11.1
INTRODUCTION
11.2
POLYMERASE CHAIN REACTION
11.2.1
PREFERENCE FOR COST-EFFECTIVE, CLINICALLY ESTABLISHED SINGLE-GENE/HOTSPOT MUTATION TESTING DRIVES MARKET
11.3
IN SITU HYBRIDIZATION
11.3.1
NEED FOR TISSUE-BASED DETECTION OF GENE AMPLIFICATION, REARRANGEMENTS, AND EXPRESSION-LINKED THERAPY SELECTION DRIVE MARKET
11.4
NEXT-GENERATION SEQUENCING
11.4.1
GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL, AND PARASITIC INFECTIONS TO DRIVE MARKET
11.5
IMMUNOHISTOCHEMISTRY
11.5.1
STRONG USE OF TISSUE-BASED PROTEIN-EXPRESSION TESTING FOR IMMUNO-ONCOLOGY AND TARGETED THERAPY SELECTION
11.6
OTHER TECHNOLOGIES
12
COMPANION DIAGNOSTICS MARKET, BY INDICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 70 Data Tables
166
12.1
INTRODUCTION
12.2
CANCER
12.2.1
LUNG CANCER
12.2.1.1
GROWING DEMAND FOR EFFECTIVE THERAPEUTIC DRUGS TO INCREASE CDX ADOPTION
12.2.2
BREAST CANCER
12.2.2.1
WIDE PREVALENCE OF BREAST CANCER AMONG WOMEN CONTRIBUTES TO THE LARGE MARKET SIZE OF THE SEGMENT
12.2.3
LEUKEMIA & LYMPHOMA
12.2.3.1
PRECISION PROFILING OF TARGETED ALTERATIONS IN HEMATOLOGIC MALIGNANCIES
12.2.4
COLORECTAL CANCER
12.2.4.1
INTEGRATION OF BIOMARKER TESTING FOR TARGETED AND IMMUNOTHERAPY SELECTION
12.2.5
MELANOMA
12.2.5.1
HIGH IMMUNOTHERAPY AND TARGETED THERAPY USE BASED ON MOLECULAR STATUS
12.2.6
OTHER CANCERS
12.3
NEUROLOGICAL DISEASES
12.3.1
RISING BURDEN OF NEURODEGENERATIVE DISEASES TO DRIVE MARKET
12.4
CARDIOVASCULAR DISEASES
12.4.1
RISING GLOBAL INCIDENCE OF CARDIOVASCULAR PATIENTS TO EXPEDITE GROWTH
12.5
INFECTIOUS DISEASES
12.5.1
INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL SEGMENT GROWTH
12.6
OTHER INDICATIONS
13
COMPANION DIAGNOSTICS MARKET VOLUME ANALYSIS FOR CANCER, BY REGION (NUMBER OF TESTS)
Comprehensive Coverage of Major Geographical Regions with Detailed Country-specific Data
204
14
COMPANION DIAGNOSTICS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 13 Data Tables
205
14.1
INTRODUCTION
14.2
CLINICAL DIAGNOSTICS
14.2.1
INCREASING USE OF CDX TESTING FOR REAL-TIME THERAPY SELECTION IN ONCOLOGY AND PRECISION MEDICINE
14.3
RESEARCH USE
14.3.1
RISING BIOMARKER DISCOVERY AND PHARMA-LED DRUG–DIAGNOSTIC CO-DEVELOPMENT PROGRAMS
15
COMPANION DIAGNOSTICS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 25 Data Tables
213
15.1
INTRODUCTION
15.2
PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
15.2.1
RISING PHARMA-LED DRUG–DIAGNOSTIC CO-DEVELOPMENT FOR TARGETED THERAPIES AND IMMUNOTHERAPIES DRIVES MARKET
15.3
REFERENCE LABORATORIES
15.3.1
INCREASING DEMAND FOR OUTSOURCED HIGH-COMPLEXITY MOLECULAR AND GENOMIC CDX TESTING
15.4
CONTRACT RESEARCH ORGANIZATIONS
15.4.1
INCREASING USE OF BIOMARKER-DRIVEN CLINICAL TRIALS AND CDX-ENABLED DRUG DEVELOPMENT PROGRAMS
15.5
OTHER END USERS
16
COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH CDX
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 13 Data Tables
228
16.1
INTRODUCTION
16.2
MONOCLONAL ANTIBODIES
16.2.1
RISING USE OF BIOMARKER-GUIDED MONOCLONAL ANTIBODY THERAPIES IN ONCOLOGY AND IMMUNO-ONCOLOGY
16.3
CELL & GENE THERAPY
16.3.1
INCREASING NEED FOR GENETIC, ANTIGEN, AND PATIENT-ELIGIBILITY TESTING IN ADVANCED PERSONALIZED THERAPIES
17
COMPANION DIAGNOSTICS MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 14 Countries | 210 Data Tables.
236
17.1
INTRODUCTION
17.2
NORTH AMERICA
17.2.1
US
17.2.1.1
PRESENCE OF ADVANCED HEALTHCARE INFRASTRUCTURE TO AUGMENT GROWTH
17.2.2
CANADA
17.2.2.1
EXPANDING PUBLIC ONCOLOGY TESTING INFRASTRUCTURE AND GROWING BIOMARKER-BASED CANCER CARE
17.3
EUROPE
17.3.1
GERMANY
17.3.1.1
ADVANCED MOLECULAR PATHOLOGY INFRASTRUCTURE AND STRONG ONCOLOGY TESTING ADOPTION
17.3.2
UK
17.3.2.1
NHS-LED GENOMIC MEDICINE INFRASTRUCTURE AND NATIONAL TEST DIRECTORY-BASED ACCESS
17.3.3
FRANCE
17.3.3.1
NATIONAL CANCER PROGRAMS AND STRUCTURED MOLECULAR ONCOLOGY NETWORKS
17.3.4
ITALY
17.3.4.1
EXPANDING MOLECULAR ONCOLOGY ADOPTION ACROSS REGIONAL CANCER CENTERS
17.3.5
SWITZERLAND
17.3.5.1
HIGH-VALUE PRECISION MEDICINE ENVIRONMENT AND STRONG PHARMA-DIAGNOSTICS PRESENCE
17.3.6
SPAIN
17.3.6.1
INCREASING ADOPTION OF BIOMARKER-GUIDED ONCOLOGY ACROSS PUBLIC HOSPITAL NETWORKS
17.3.7
REST OF EUROPE
17.4
ASIA PACIFIC
17.4.1
CHINA
17.4.1.1
LARGE ONCOLOGY PATIENT POOL AND RAPID EXPANSION OF DOMESTIC PRECISION MEDICINE INFRASTRUCTURE
17.4.2
JAPAN
17.4.2.1
UNIVERSAL HEALTHCARE REIMBURSEMENT POLICY TO FOSTER GROWTH
17.4.3
INDIA
17.4.3.1
INCREASED PRIVATE AND PUBLIC INVESTMENTS TO BOLSTER GROWTH
17.4.4
SOUTH KOREA
17.4.4.1
ADVANCED HEALTHCARE INFRASTRUCTURE AND STRONG ADOPTION OF PRECISION ONCOLOGY TECHNOLOGIES
17.4.5
AUSTRALIA
17.4.5.1
STRONG ONCOLOGY CARE INFRASTRUCTURE AND HIGH BIOMARKER TESTING NEED IN MELANOMA AND SOLID TUMORS
17.4.6
REST OF ASIA PACIFIC
17.5
LATIN AMERICA
17.5.1
BRAZIL
17.5.1.1
LARGEST ONCOLOGY PATIENT POOL IN LATIN AMERICA AND GROWING ADOPTION OF PRECISION ONCOLOGY IN PRIVATE HEALTHCARE
17.5.2
MEXICO
17.5.2.1
EXPANDING ONCOLOGY CARE NETWORKS AND INCREASING USE OF BIOMARKER TESTING IN URBAN CANCER CENTERS
17.5.3
REST OF LATIN AMERICA
17.6
MIDDLE EAST & AFRICA
17.6.1
GCC COUNTRIES
17.6.1.1
GROWING PUBLIC HEALTHCARE FUNDING TO DRIVE MARKET
17.6.2
REST OF MIDDLE EAST & AFRICA
18
COMPETITIVE LANDSCAPE
Identify market leaders and emerging disruptors shaping the companion diagnostics competitive landscape.
327
18.1
INTRODUCTION
18.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
18.2.1
OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN COMPANION DIAGNOSTICS MARKET
18.3
REVENUE ANALYSIS, 2023–2025
18.4
MARKET SHARE ANALYSIS, 2025
18.4.1
GLOBAL MARKET SHARE ANALYSIS, 2025
18.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
18.5.1
STARS
18.5.2
EMERGING LEADERS
18.5.3
PERVASIVE PLAYERS
18.5.4
PARTICIPANTS
18.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
18.5.5.1
COMPANY FOOTPRINT
18.5.5.2
REGION FOOTPRINT
18.5.5.3
PRODUCT & SERVICE FOOTPRINT
18.5.5.4
INDICATION FOOTPRINT
18.5.5.5
TECHNOLOGY FOOTPRINT
18.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
18.6.1
PROGRESSIVE COMPANIES
18.6.2
RESPONSIVE COMPANIES
18.6.3
DYNAMIC COMPANIES
18.6.4
STARTING BLOCKS
18.6.5
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
18.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
18.6.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
18.7
COMPANY VALUATION & FINANCIAL METRICS
18.7.1
FINANCIAL METRICS
18.7.2
COMPANY VALUATION
18.8
BRAND/PRODUCT COMPARISON
18.9
COMPETITIVE SCENARIO
18.9.1
PRODUCT LAUNCHES & APPROVALS
18.9.2
DEALS
18.9.3
EXPANSIONS
18.9.4
OTHER DEVELOPMENTS
19
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
344
19.1
KEY PLAYERS
19.1.1
F. HOFFMANN-LA ROCHE LTD.
19.1.1.1
BUSINESS OVERVIEW
19.1.1.2
PRODUCTS/SERVICES/SOLUTIONS OFFERED
19.1.1.3
RECENT DEVELOPMENTS
19.1.1.3.1
PRODUCT LAUNCHES & APPROVALS
19.1.1.3.2
DEALS
19.1.1.3.3
EXPANSIONS
19.1.1.4
MNM VIEW
19.1.1.4.1
KEY STRENGTHS
19.1.1.4.2
STRATEGIC CHOICES
19.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
19.1.2
AGILENT TECHNOLOGIES, INC
19.1.3
QIAGEN
19.1.4
THERMO FISHER SCIENTIFIC INC.
19.1.5
ABBOTT
19.1.6
DANAHER
19.1.7
ILLUMINA, INC.
19.1.8
BIOMÉRIEUX
19.1.9
MYRIAD GENETICS, INC.
19.1.10
SYSMEX CORPORATION
19.1.11
QUEST DIAGNOSTICS
19.1.12
GUARDANT HEALTH
19.1.13
ICON PLC
19.1.14
TEMPUS AI, INC.
19.1.15
CARIS LIFE SCIENCES, INC.
19.2
OTHER PLAYERS
19.2.1
THE ALMAC GROUP
19.2.2
AMOY DIAGNOSTICS CO., LTD.
19.2.3
ARUP LABORATORIES
19.2.4
ABNOVA CORPORATION
19.2.5
INVIVOSCRIBE, INC.
19.2.6
Q² SOLUTIONS
19.2.7
CREATIVE BIOLABS
19.2.8
PILLAR BIOSCIENCES
19.2.9
ENTROGEN, INC.
19.2.10
BIOCARTIS
20
RESEARCH METHODOLOGY
406
20.1
RESEARCH DATA
20.1.1
SECONDARY DATA
20.1.1.1
LIST OF SECONDARY SOURCES
20.1.1.2
KEY DATA FROM SECONDARY SOURCES
20.1.2
PRIMARY DATA
20.1.2.1
LIST OF PRIMARY SOURCES
20.1.2.2
KEY DATA FROM PRIMARY SOURCES
20.1.2.3
KEY INDUSTRY INSIGHTS
20.1.2.4
BREAKDOWN OF PRIMARY INTERVIEWS
20.2
MARKET SIZE ESTIMATION
20.2.1
TOTAL MARKET SIZE: COMPANION DIAGNOSTICS MARKET
20.2.2
BOTTOM-UP APPROACH
20.2.2.1
APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS
20.2.2.2
APPROACH 2: STUDY OF ANNUAL REPORTS AND INVESTOR PRESENTATIONS
20.2.2.3
APPROACH 3: PRIMARY INTERVIEWS
20.2.2.4
GROWTH FORECAST
20.2.2.5
CAGR PROJECTIONS
20.2.3
TOP-DOWN APPROACH
20.3
DATA TRIANGULATION
20.4
RESEARCH ASSUMPTIONS
20.4.1
STUDY-RELATED ASSUMPTIONS
20.5
STUDY ASSUMPTIONS
20.5.1
PARAMETRIC ASSUMPTIONS
20.5.2
GROWTH RATE ASSUMPTIONS
20.6
RESEARCH LIMITATIONS
20.7
RISK ASSESSMENT
21
APPENDIX
418
21.1
DISCUSSION GUIDE
21.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
21.3
CUSTOMIZATION OPTIONS
21.4
RELATED REPORTS
21.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
COMPANION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 2
GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030
TABLE 3
NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 4
EUROPE: MACROECONOMIC INDICATORS
TABLE 5
ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 6
LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 7
MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 8
COMPANION DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 9
AVERAGE SELLING PRICE TREND OF COMPANION DIAGNOSTICS PRODUCTS, BY KEY PLAYER, 2024–2026 (USD)
TABLE 10
AVERAGE SELLING PRICE TREND OF COMPANION DIAGNOSTICS PRODUCTS, BY REGION, 2024–2026 (USD)
TABLE 11
AVERAGE SELLING PRICE TREND OF COMPANION DIAGNOSTICS, TECHNOLOGY TYPE, BY REGION, 2024–2026 (USD)
TABLE 12
IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 13
EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 14
COMPANION DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 15
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 16
KEY PATENTS IN COMPANION DIAGNOSTICS MARKET, 2022–2026
TABLE 17
KEY COMPANIES IMPLEMENTING AI IN COMPANION DIAGNOSTICS
TABLE 18
CLASSIFICATION OF IVD DEVICES IN EUROPE
TABLE 19
TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
TABLE 20
CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA
TABLE 21
NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22
EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23
ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24
LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25
REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
TABLE 27
KEY BUYING CRITERIA, BY PRODUCT & SERVICE
TABLE 28
ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 29
MOLECULAR INFECTIOUS DISEASE TESTING MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
TABLE 30
COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 31
ASSAYS, KITS, AND REAGENTS OFFERED BY KEY PLAYERS
TABLE 32
COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 33
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34
EUROPE: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 38
INSTRUMENTS/SYSTEMS OFFERED BY KEY PLAYERS
TABLE 39
COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY REGION, 2024–2031 (USD MILLION)
TABLE 40
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41
EUROPE: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY REGION, 2024–2031 (USD MILLION)
TABLE 45
KEY SOFTWARE & SERVICES AVAILABLE IN MARKET
TABLE 46
COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 47
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48
EUROPE: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 52
COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 53
EXAMPLES OF FDA-APPROVED TISSUE-BASED COMPANION DIAGNOSTICS PRODUCTS
TABLE 54
COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 55
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56
EUROPE: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 60
EXAMPLES OF FDA-APPROVED BLOOD-BASED COMPANION DIAGNOSTICS PRODUCTS
TABLE 61
COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 62
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63
EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 67
EXAMPLES OF COMPANION DIAGNOSTICS PRODUCTS FOR OTHER SAMPLE TYPES
TABLE 68
COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2024–2031 (USD MILLION)
TABLE 69
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70
EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2024–2031 (USD MILLION)
TABLE 74
COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 75
COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION
TABLE 76
PCR TESTS/KITS OFFERED BY KEY PLAYERS
TABLE 77
COMPANION DIAGNOSTICS MARKET FOR PCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 78
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79
EUROPE: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR PCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 83
ISH TESTS/KITS OFFERED BY KEY PLAYERS
TABLE 84
COMPANION DIAGNOSTICS MARKET FOR ISH, BY REGION, 2024–2031 (USD MILLION)
TABLE 85
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86
EUROPE: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR ISH, BY REGION, 2024–2031 (USD MILLION)
TABLE 90
NGS TESTS/KITS OFFERED BY KEY PLAYERS
TABLE 91
COMPANION DIAGNOSTICS MARKET FOR NGS, BY REGION, 2024–2031 (USD MILLION)
TABLE 92
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93
EUROPE: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR NGS, BY REGION, 2024–2031 (USD MILLION)
TABLE 97
IHC TESTS/KITS OFFERED BY KEY PLAYERS
TABLE 98
COMPANION DIAGNOSTICS MARKET FOR IHC, BY REGION, 2024–2031 (USD MILLION)
TABLE 99
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100
EUROPE: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR IHC, BY REGION, 2024–2031 (USD MILLION)
TABLE 104
COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 105
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106
EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 110
COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 111
ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2025 VS. 2040
TABLE 112
COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 113
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114
EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 118
COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 119
COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 120
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121
EUROPE: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 125
BREAST CANCER TESTING PRODUCTS OFFERED BY KEY PLAYERS
TABLE 126
COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 127
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128
EUROPE: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 132
COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY REGION, 2024–2031 (USD MILLION)
TABLE 133
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134
EUROPE: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY REGION, 2024–2031 (USD MILLION)
TABLE 138
COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 139
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140
EUROPE: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 144
COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY REGION, 2024–2031 (USD MILLION)
TABLE 145
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146
EUROPE: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY REGION, 2024–2031 (USD MILLION)
TABLE 150
COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 151
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152
EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 156
COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 157
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158
EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 162
COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 163
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164
EUROPE: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 168
COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 169
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170
EUROPE: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 174
COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 175
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176
EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 178
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 180
COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2024–2031 (NUMBER OF TESTS IN MILLION)
TABLE 181
COMPANION DIAGNOSTICS, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 182
COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 183
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184
EUROPE: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 185
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 188
COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY REGION, 2024–2031 (USD MILLION)
TABLE 189
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190
EUROPE: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 191
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY REGION, 2024–2031 (USD MILLION)
TABLE 194
COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 195
COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 196
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197
EUROPE: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 201
COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 202
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203
EUROPE: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 207
COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 208
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209
EUROPE: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 213
COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 214
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215
EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 219
COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH CDX, 2024–2031 (USD MILLION)
TABLE 220
COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 221
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222
EUROPE: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 226
COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY REGION, 2024–2031 (USD MILLION)
TABLE 227
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228
EUROPE: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 229
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232
COMPANION DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 233
NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 234
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 236
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 237
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 238
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 240
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 241
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 242
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 243
US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 244
US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 245
US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 246
US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 247
US: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 248
US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 249
US: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 250
US: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 251
CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 252
CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 253
CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 254
CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 255
CANADA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 256
CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 257
CANADA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 258
CANADA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 259
EUROPE: MACROECONOMIC INDICATORS
TABLE 260
EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261
EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 262
EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 263
EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 264
EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 265
EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 266
EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 267
EUROPE: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 268
EUROPE: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 269
GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 270
GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 271
GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 272
GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 273
GERMANY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 274
GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 275
GERMANY: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 276
GERMANY: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 277
UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 278
UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 279
UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 280
UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 281
UK: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 282
UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 283
UK: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 284
UK: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 285
FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 286
FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 287
FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 288
FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 289
FRANCE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 290
FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 291
FRANCE: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 292
FRANCE: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 293
ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 294
ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 295
ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 296
ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 297
ITALY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 298
ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 299
ITALY: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 300
ITALY: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 301
SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 302
SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 303
SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 304
SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 305
SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 306
SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 307
SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 308
SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 309
SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 310
SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 311
SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 312
SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 313
SPAIN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 314
SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 315
SPAIN: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 316
SPAIN: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 317
REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 318
REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 319
REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 320
REST OF EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 321
REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 322
REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 323
REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 324
REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 325
ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 326
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 327
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 328
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 329
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 330
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 331
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 332
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 333
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 334
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 335
CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 336
CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 337
CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 338
CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 339
CHINA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 340
CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 341
CHINA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 342
CHINA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 343
JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 344
JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 345
JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 346
JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 347
JAPAN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 348
JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 349
JAPAN: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 350
JAPAN: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 351
INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 352
INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 353
INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 354
INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 355
INDIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 356
INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 357
INDIA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 358
INDIA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 359
SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 360
SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 361
SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 362
SOUTH KOREA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 363
SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 364
SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 365
SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 366
SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 367
AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 368
AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 369
AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 370
AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 371
AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 372
AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 373
AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 374
AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 375
REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 376
REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 377
REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 378
REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 379
REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 380
REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 381
REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 382
REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 383
LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 384
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 385
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 386
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 387
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 388
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 389
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 390
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 391
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 392
LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 393
BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 394
BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 395
BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 396
BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 397
BRAZIL: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 398
BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 399
BRAZIL: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 400
BRAZIL: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 401
MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 402
MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 403
MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 404
MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 405
MEXICO: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 406
MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 407
MEXICO: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 408
MEXICO: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 409
REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 410
REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 411
REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 412
REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 413
REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 414
REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 415
REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 416
REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 417
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 418
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 419
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 420
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 421
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 422
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 423
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 424
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 425
MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 426
GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 427
GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 428
GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 429
GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 430
GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 431
GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 432
GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 433
GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 434
REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 435
REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 436
REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 437
REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
TABLE 438
REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 439
REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 440
REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION)
TABLE 441
REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 442
OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN COMPANION DIAGNOSTICS MARKET, JANUARY 2023−MAY 2026
TABLE 443
COMPANION DIAGNOSTICS MARKET: DEGREE OF COMPETITION
TABLE 444
COMPANION DIAGNOSTICS MARKET: REGION FOOTPRINT
TABLE 445
COMPANION DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
TABLE 446
COMPANION DIAGNOSTICS MARKET: INDICATION FOOTPRINT
TABLE 447
COMPANION DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
TABLE 448
COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 449
COMPANION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
TABLE 450
COMPANION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
TABLE 451
COMPANION DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026
TABLE 452
COMPANION DIAGNOSTICS MARKET: DEALS, JANUARY 2023–MAY 2026
TABLE 453
COMPANION DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2023–MAY 2026
TABLE 454
COMPANION DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026
TABLE 455
F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 456
F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 457
F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 458
F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023–APRIL 2026
TABLE 459
F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2023–APRIL 2026
TABLE 460
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 461
AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 462
AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 463
AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 464
QIAGEN: COMPANY OVERVIEW
TABLE 465
QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 466
QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–MAY 2026
TABLE 467
QIAGEN: DEALS, JANUARY 2023–MAY 2026
TABLE 468
QIAGEN: EXPANSIONS, JANUARY 2023–MAY 2026
TABLE 469
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 470
THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 471
THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026
TABLE 472
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 473
ABBOTT: COMPANY OVERVIEW
TABLE 474
ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 475
ABBOTT: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026
TABLE 476
ABBOTT: DEALS, JANUARY 2023–APRIL 2026
TABLE 477
DANAHER: COMPANY OVERVIEW
TABLE 478
DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 479
DANAHER: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026
TABLE 480
DANAHER: DEALS, JANUARY 2023–APRIL 2026
TABLE 481
ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 482
ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 483
ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 484
ILLUMINA, INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 485
BIOMÉRIEUX: COMPANY OVERVIEW
TABLE 486
BIOMÉRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 487
BIOMÉRIEUX: DEALS, JANUARY 2023–APRIL 2026
TABLE 488
MYRIAD GENETICS, INC.: COMPANY OVERVIEW
TABLE 489
MYRIAD GENETICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 490
MYRIAD GENETICS, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 491
MYRIAD GENETICS, INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 492
SYSMEX CORPORATION: COMPANY OVERVIEW
TABLE 493
SYSMEX CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 494
SYSMEX CORPORATION: DEALS, JANUARY 2023-MAY 2026
TABLE 495
QUEST DIAGNOSTICS: COMPANY OVERVIEW
TABLE 496
QUEST DIAGNOSTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 497
QUEST DIAGNOSTICS: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 498
GUARDANT HEALTH: COMPANY OVERVIEW
TABLE 499
GUARDANT HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 500
GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MAY 2026
TABLE 501
GUARDANT HEALTH: DEALS, JANUARY 2023-MAY 2026
TABLE 502
ICON PLC: COMPANY OVERVIEW
TABLE 503
ICON PLC: SERVICES/PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 504
TEMPUS AI, INC.: COMPANY OVERVIEW
TABLE 505
TEMPUS AI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 506
TEMPUS AI, INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 507
TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026
TABLE 508
CARIS LIFE SCIENCES, INC.: COMPANY OVERVIEW
TABLE 509
CARIS LIFE SCIENCES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 510
CARIS LIFE SCIENCES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MAY 2026
TABLE 511
COMPANION DIAGNOSTICS MARKET: RISK ASSESSMENT
LIST OF FIGURES
FIGURE 1
COMPANION DIAGNOSTICS MARKET SEGMENTATION
FIGURE 2
KEY INSIGHTS & MARKET HIGHLIGHTS
FIGURE 3
GLOBAL COMPANION DIAGNOSTICS MARKET, 2024–2031
FIGURE 4
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN COMPANION DIAGNOSTICS MARKET, 2023–2025
FIGURE 5
DISRUPTIVE TRENDS IMPACTING GROWTH OF COMPANION DIAGNOSTICS MARKET
FIGURE 6
HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN COMPANION DIAGNOSTICS MARKET, 2025
FIGURE 7
ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 8
INCREASING ADOPTION OF TARGETED THERAPIES TO DRIVE MARKET
FIGURE 9
ASSAYS, KITS, AND REAGENTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 10
PCR SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 11
CANCER SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 12
TISSUE SAMPLE SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 13
MONOCLONAL ANTIBODIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 14
CLINICAL DIAGNOSTICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 15
ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 16
COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 17
COMPANION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 18
COMPANION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 19
COMPANION DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
FIGURE 20
COMPANION DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 21
COMPANION DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 22
DEALS & FUNDING ACTIVITIES IN COMPANION DIAGNOSTICS MARKET
FIGURE 23
PATENT ANALYSIS FOR COMPANION DIAGNOSTICS MARKET, JANUARY 2016–DECEMBER 2025
FIGURE 24
MARKET POTENTIAL OF AI IN COMPANION DIAGNOSTICS MARKET
FIGURE 25
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
FIGURE 26
KEY BUYING CRITERIA, BY PRODUCT & SERVICE
FIGURE 27
NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
FIGURE 28
ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
FIGURE 29
REVENUE ANALYSIS OF KEY PLAYERS IN COMPANION DIAGNOSTICS MARKET, 2023–2025 (USD MILLION)
FIGURE 30
COMPANION DIAGNOSTICS MARKET SHARE ANALYSIS, 2025 (GLOBAL)
FIGURE 31
COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 32
COMPANION DIAGNOSTICS MARKET: COMPANY FOOTPRINT
FIGURE 33
COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 34
EV/EBITDA OF KEY VENDORS
FIGURE 35
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 36
COMPANION DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON FOR COMPANION DIAGNOSTICS
FIGURE 37
F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
FIGURE 38
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 39
QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 40
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 41
ABBOTT: COMPANY SNAPSHOT (2025)
FIGURE 42
DANAHER: COMPANY SNAPSHOT (2025)
FIGURE 43
ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 44
BIOMÉRIEUX: COMPANY SNAPSHOT (2025)
FIGURE 45
MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2025)
FIGURE 46
SYSMEX CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 47
QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2025)
FIGURE 48
GUARDANT HEALTH: COMPANY SNAPSHOT (2025)
FIGURE 49
ICON PLC: COMPANY SNAPSHOT (2024)
FIGURE 50
TEMPUS AI, INC.: COMPANY SNAPSHOT (2025)
FIGURE 51
CARIS LIFE SCIENCES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 52
RESEARCH DESIGN
FIGURE 53
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 54
DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030): IMPACT ON MARKET GROWTH AND CAGR
FIGURE 55
TOP-DOWN APPROACH
FIGURE 56
DATA TRIANGULATION
Methodology
This study involved four major activities in estimating the current size of the companion diagnostics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology,. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global companion diagnostics market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the companion diagnostics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
A companion diagnostic (CDx) is an in vitro diagnostic (IVD) device that is used to make biomarker assessments to identify whether a patient with certain chronic diseases, such as cancer, infectious diseases, and cardiovascular diseases, could benefit from a particular drug provides information essential for the safe and effective use of a specific therapeutic product, particularly targeted therapies and biologics. These tests help identify patients who are most likely to benefit from a treatment, may experience adverse reactions, or require therapy selection based on biomarker or molecular profiling. The market includes assay kits, reagents, instruments, software, and laboratory testing services across technologies such as polymerase chain reaction, next-generation sequencing, immunohistochemistry, and in situ hybridization, among others.
Key Stakeholders
- Manufacturers and Distributors of Companion Diagnostics Products
- In Vitro Diagnostic (IVD) Companies
- Hospital Laboratories
- Diagnostic Laboratories
- Diagnostics Suppliers
- Pharmaceutical Companies
- Research Laboratories and Academic Institutes
- Clinical Research Organizations (CROs)
- Research & Development (R&D) Companies
- Academic Medical Centers/Government Research Organizations
- Companion Diagnostics Service Providers
- Government Associations
- Market Research & Consulting Firms
- Venture Capitalists & Investors
Report Objectives
- To define, describe, segment, and forecast the global companion diagnostics market, by product & service, technology, Indication, Sample type, Drug Class Associated with CDX, Application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall companion diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to six regions: North America(US and Canada), Europe (Germany, France, the UK, Switzerland Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC and the Rest of Middle East], and Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, collaborations, expansions, and other developments
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe companion diagnostics market, by country
- Further breakdown of the Rest of Asia Pacific companion diagnostics market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Companion Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Growth opportunities and latent adjacency in Companion Diagnostics Market
Alisa
Jul, 2022
What is the Companion Diagnostics Market trend by Product (Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User (Pharma Companies, CROs), Regional Analysis - Global Forecast to 2031.
Alan
Dec, 2022
Companion Diagnostics Market Report provides the global forecasts for the next five years. Companies like ResearchDx is profiled as one of the key players in this report. Included the comprehensive 360 degree competitive mapping by profiling major players of Companion Diagnostics Market. Key Questions Addressed in the Report: • Where will all these products & services take the industry in the mid to long term? • What are the growth opportunities in the Companion Diagnostics Market across major regions in the future? • Which are the key players in the market and how intense is the competition? • What are the current industry developments for companion diagnostics? We have given a comprehensive 360 degree competitive mapping by profiling major players of Companion Diagnostics Market..